Fibrin structure in organized thrombotic material removed during pulmonary artery endarterectormy: the effect of vessel calibre

Journal of Thrombosis and Thrombolysis

Volumn 42, Issue 2, 2016, Pages 212-217

  Mazur, Piotr ^a,b   Gawęda, Bogusław ^b   Natorska, Joanna ^a,b   Ząbczyk, Michał ^a,b   Undas, Anetta ^a,b   Sadowski, Jerzy ^a,b   Kopeć, Grzegorz ^a,b   Waligóra, Marcin ^b   Podolec, Piotr ^a,b   Kapelak, Bogusław ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Chronic thromboembolic pulmonary hypertension; Fibrin; Pulmonary arteries; Thrombus architecture

Indexed keywords

FIBRIN; GLICLAZIDE; LOW MOLECULAR WEIGHT HEPARIN; METFORMIN; THROMBOPLASTIN; WARFARIN; COLLAGEN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COLLAGEN FIBER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DEEP HYPOTHERMIC CIRCULATORY ARREST; DEEP VEIN THROMBOSIS; DYSPNEA; ELASTIC FIBER; ENDARTERECTOMY; EXTRACORPOREAL CIRCULATION; FEMALE; FIBROBLAST; HEART RIGHT VENTRICLE OVERLOAD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MACROPHAGE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY ENDARTERECTORMY; PULMONARY REHABILITATION; SCANNING ELECTRON MICROSCOPY; THROMBOPHILIA; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; BLOOD CELL; ELASTIC TISSUE; PATHOLOGY; SURGERY; THROMBOSIS; ULTRASTRUCTURE;

BLOOD CELLS; COLLAGEN; ELASTIC TISSUE; ENDARTERECTOMY; FEMALE; FIBRIN; HUMANS; MIDDLE AGED; PULMONARY ARTERY; THROMBOSIS;

EID: 84975700652     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-016-1382-z     Document Type: Article

References (26)

1. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P, Thromboembolic Pulmonary Hypertension Study G (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264. doi:10.1056/NEJMoa032274
2. Jenkins D (2015) Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev 24:263–271. doi:10.1183/16000617.00000815
3. Wagenvoort CA (1995) Pathology of pulmonary thromboembolism. Chest 107:10S–17S
4. Toshner M, Pepke-Zaba J (2014) Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment. F1000Prime Rep 6:38. doi:10.12703/P6-38
5. Morris TA, Marsh JJ, Chiles PG, Kim NH, Noskovack KJ, Magana MM, Gruppo RA, Woods VL Jr (2007) Abnormally sialylated fibrinogen gamma-chains in a patient with chronic thromboembolic pulmonary hypertension. Thromb Res 119:257–259. doi:10.1016/j.thromres.2006.02.010
6. Morris TA, Marsh JJ, Chiles PG, Auger WR, Fedullo PF, Woods VL Jr (2006) Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 173:1270–1275. doi:10.1164/rccm.200506-916OC
7. Vikerfors A, Svenungsson E, Agren A, Mobarrez F, Bremme K, Holmstrom M, Eelde A, Bruzelius M, Elgue G, Wallen H, Antovic A (2014) Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. Thromb Res 133:936–944. doi:10.1016/j.thromres.2014.02.023
8. Mirrakhimov AE, Hill NS (2014) Primary antiphospholipid syndrome and pulmonary hypertension. Curr Pharm Des 20:545–551
9. Mazur P, Sobczynski R, Zabczyk M, Babiarczyk P, Sadowski J, Undas A (2013) Architecture of fibrin network inside thrombotic material obtained from the right atrium and pulmonary arteries: flow and location matter. J Thromb Thrombolysis 35:127–129. doi:10.1007/s11239-012-0806-7
10. Thistlethwaite PA, Mo M, Madani MM, Deutsch R, Blanchard D, Kapelanski DP, Jamieson SW (2002) Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg 124:1203–1211. doi:10.1067/mtc.2002.127313
11. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306. doi:10.1111/j.1538-7836.2006.01753.x
12. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the S, Standardisation Committee of the International Society on T, Haemostasis (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7:1737–1740. doi:10.1111/j.1538-7836.2009.03555.x
13. Tripodi A, de Groot PG, Pengo V (2011) Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 270:110–122. doi:10.1111/j.1365-2796.2011.02362.x
14. Mazur P, Sokolowski G, Hubalewska-Dydejczyk A, Placzkiewicz-Jankowska E, Undas A (2014) Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications. Thromb Res 134:510–517. doi:10.1016/j.thromres.2014.05.041
15. Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, Ciepluch K, Tracz W (2009) Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114:4272–4278. doi:10.1182/blood-2009-05-222380
16. Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, Pasowicz M, Zmudka K (2008) Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 196:551–557. doi:10.1016/j.atherosclerosis.2007.05.028
17. Brass LF, Diamond SL (2016) Transport physics and biorheology in the setting of haemostasis and thrombosis. J Thromb Haemost. doi:10.1111/jth.13280
18. Undas A, Ariens RA (2011) Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:e88–e99. doi:10.1161/ATVBAHA.111.230631
19. Dunn EJ, Ariens RA, Grant PJ (2005) The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48:1198–1206. doi:10.1007/s00125-005-1742-2
20. Bochenek M, Zalewski J, Sadowski J, Undas A (2013) Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease. J Thromb Thrombolysis 35:264–270. doi:10.1007/s11239-012-0821-8
21. Movahed MR, Hashemzadeh M, Jamal MM (2005) The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest 128:3568–3571. doi:10.1378/chest.128.5.3568
22. Lang I, Kerr K (2006) Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3:568–570. doi:10.1513/pats.200605-108LR
23. Qi J, Kreutzer DL (1995) Fibrin activation of vascular endothelial cells. Induction of IL-8 expression. J Immunol 155:867–876
24. Tsakadze NL, Zhao Z, D’Souza SE (2002) Interactions of intercellular adhesion molecule-1 with fibrinogen. Trends Cardiovasc Med 12:101–108
25. Barnard JW, Biro MG, Lo SK, Ohno S, Carozza MA, Moyle M, Soule HR, Malik AB (1995) Neutrophil inhibitory factor prevents neutrophil-dependent lung injury. J Immunol 155:4876–4881
26. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR (1994) Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 89:2715–2721